Manufacturing & supply · first seen 10h ago, updated 10h ago
Enveda raises a $311M series E for pipeline of plant-discovered molecules
Enveda Therapeutics Inc. has doubled its valuation to approximately $2 billion in a $311 million series E financing, led by Catalio Capital Management, to support its pipeline of drugs to treat inflammatory and metabolic disease. Since its…
Summary from BioWorld Articles.